Copyright © 1999 by the European Society of Cardiology.
The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee’s final decision on end-points
a Cardiology Section, Heart Centre, University Hospital, Umeå, Sweden
b Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
c Department of Cardiology, Bispebjerg Hospital, Bispebjerg, Denmark
d Department of Internal Medicine, Aust-Agder Hospital, Arendal, Norway
e Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland
f Department of Cardiology, Academic Hospital, Uppsala, Sweden
revised October 1, 1998; accepted October 7, 1998
Abstract
Background A multicentre study permits rapid recruitment of a large number of patients. However, there is a risk of heterogeneities in end-point evaluations, as complex definitions of criteria are interpreted by several local investigators from different hospitals. Reports discussing end-point evaluation are sparse. The TRIM trial was a multicentre trial of a thrombin inhibitor in patients with unstable angina or non-Q myocardial infarction. In this study, an independent end-point committee evaluated all the reported events of death, acute myocardial infarction and refractory angina pectoris in order to obtain uniform judgements of major end-points.
Study aims To describe the work of the end-point committee, to analyse its possible effect on the final study results and to discuss the impact on the design of future trials.
Method The end-point committee consisted of four members, one from each participating country. After the data were processed by the study monitors, completed case record forms and patient files for patients with reported end-points were mailed to the national member of the end-point committee for judgement. The end-point committee met regularly and made final decisions about the end-points. The work of the end-point committee was documented on a separate case record form.
Results The end-point committee assessed 246 events of death, acute myocardial infarction and refractory angina pectoris in 187 of the 1209 patients (15·5%) in the TRIM trial. Misinterpretation of the index event, an inclusion myocardial infarction, as an early cardiac event was found in 12 patients. After end-point committee judgements, the number of patients with acute myocardial infarction or refractory angina pectoris during 30 days of follow-up was reduced from 177 to 153 (13·6% reduction). The classification of events was changed in 53 of 187 patients (28·3%) with death, acute myocardial infarction or refractory angina pectoris. The data assessed by the safety committee was significantly different from the final database after end-point committee judgements.
Conclusion The end-point committee corrected misinterpretations in such a high proportion of cases that the final results differed significantly from the preliminary results delivered to the safety committee. End-point judgements by an end-point committee should be performed in multicentre clinical trials to improve the quality and reliability of study results.
Key Words: Multicentre • clinical trials • data monitoring • study organisation • end-point
f1 Correspondence: Dr Ulf Näslund, Cardiology Section, Heart Centre, University Hospital, SE-901 85 Ume
, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Berger, L. Elliott, D. Gallup, M. Roe, C. B. Granger, P. W. Armstrong, R. J. Simes, H. D. White, F. Van de Werf, E. J. Topol, et al. Sex Differences in Mortality Following Acute Coronary Syndromes JAMA, August 26, 2009; 302(8): 874 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pogue, S. D Walter, and S. Yusuf Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs Clinical Trials, June 1, 2009; 6(3): 239 - 251. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Ninomiya, G. Donnan, N. Anderson, C. Bladin, B. Chambers, G. Gordon, N. Sharpe, J. Chalmers, M. Woodward, B. Neal, et al. Effects of the End Point Adjudication Process on the Results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Stroke, June 1, 2009; 40(6): 2111 - 2115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L Nolen, B. F Dimmick, L. Ostrosky-Zeichner, A. S Kendrick, C. Sable, A. Ngai, and D. Wallace A web-based endpoint adjudication system for interim analyses in clinical trials Clinical Trials, February 1, 2009; 6(1): 60 - 66. [Abstract] [PDF]
|
|
|
|
 |
|
 L. P McGarvey, M. John, J. A Anderson, M. Zvarich, and R. A Wise Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee Thorax, May 1, 2007; 62(5): 411 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Jacobsen, G. S. Wagner, L. Holmvang, F. Kontny, L. Wallentin, S. Husted, E. Swahn, E. Stahle, R. Steffensen, and P. Clemmensen Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population Eur. Heart J., January 2, 2005; 26(2): 112 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Lauer and E. J. Topol Clinical Trials--Multiple Treatments, Multiple End Points, and Multiple Lessons JAMA, May 21, 2003; 289(19): 2575 - 2577. [Full Text] [PDF]
|
|
|
|
|
|
J Oldgren, L Wallentin, L Grip, R Linder, B.L Norgaard, and A Siegbahn Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease Eur. Heart J., January 1, 2003; 24(1): 86 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Oldgren, R. Linder, L. Grip, A. Siegbahn, and L. Wallentin Coagulation Activity and Clinical Outcome in Unstable Coronary Artery Disease Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 1059 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fagerberg Screening, endpoint classification, and safety monitoring in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Eur J Heart Fail, September 1, 2000; 2(3): 315 - 324. [Abstract] [Full Text] [PDF]
|
|